BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors

Anthony C. Faber, Ryan B. Corcoran, Hiromichi Ebi, Lecia V. Sequist, Belinda A. Waltman, Euiheon Chung, Joao Incio, Subba R. Digumarthy, Sarah F. Pollack, Youngchul Song, Alona Muzikansky, Eugene Lifshits, Sylvie Roberge, Erik J. Coffman, Cyril H. Benes, Henry L. Gómez, José Baselga, Carlos L. Arteaga, Miguel N. Rivera, Dora Dias-SantagataRakesh K. Jain, Jeffrey A. Engelman

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Cancers with specific genetic mutations are susceptible to selective kinase inhibitors. However, there is a wide spectrum of benefit among cancers harboring the same sensitizing genetic mutations. Herein, we measured apoptotic rates among cell lines sharing the same driver oncogene following treatment with the corresponding kinase inhibitor. There was a wide range of kinase inhibitor-induced apoptosis despite comparable inhibition of the target and associated downstream signaling pathways. Surprisingly, pretreatment RNA levels of the BH3-only pro-apoptotic BIM strongly predicted the capacity of EGFR, HER2, and PI3K inhibitors to induce apoptosis in EGFR-mutant, HER2-amplified, and PIK3CA-mutant cancers, respectively, but BIM levels did not predict responsiveness to standard chemotherapies. Furthermore, BIM RNA levels in EGFR-mutant lung cancer specimens predicted response and duration of clinical benefit from EGFR inhibitors. These findings suggest assessment of BIM levels in treatment-naïve tumor biopsies may indicate the degree of benefit from single-agent kinase inhibitors in multiple oncogene-addiction paradigms. Significance: In several oncogene-addiction paradigms, assessment of BIM RNA levels identifies those cancers that fail to have substantial apoptotic responses to kinase inhibitors. BIM RNA levels may be assessed in diagnostic cancer specimens to predict which patients will receive less benefit from single-agent kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)352-365
Number of pages14
JournalCancer Discovery
Volume1
Issue number4
DOIs
StatePublished - Sep 1 2011

Fingerprint

Phosphotransferases
Oncogenes
RNA
Neoplasms
Therapeutics
Apoptosis
Mutation
Phosphatidylinositol 3-Kinases
Lung Neoplasms
Biopsy
Drug Therapy
Cell Line

ASJC Scopus subject areas

  • Oncology

Cite this

Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., ... Engelman, J. A. (2011). BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors. Cancer Discovery, 1(4), 352-365. https://doi.org/10.1158/2159-8290.CD-11-0106

BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors. / Faber, Anthony C.; Corcoran, Ryan B.; Ebi, Hiromichi; Sequist, Lecia V.; Waltman, Belinda A.; Chung, Euiheon; Incio, Joao; Digumarthy, Subba R.; Pollack, Sarah F.; Song, Youngchul; Muzikansky, Alona; Lifshits, Eugene; Roberge, Sylvie; Coffman, Erik J.; Benes, Cyril H.; Gómez, Henry L.; Baselga, José; Arteaga, Carlos L.; Rivera, Miguel N.; Dias-Santagata, Dora; Jain, Rakesh K.; Engelman, Jeffrey A.

In: Cancer Discovery, Vol. 1, No. 4, 01.09.2011, p. 352-365.

Research output: Contribution to journalArticle

Faber, AC, Corcoran, RB, Ebi, H, Sequist, LV, Waltman, BA, Chung, E, Incio, J, Digumarthy, SR, Pollack, SF, Song, Y, Muzikansky, A, Lifshits, E, Roberge, S, Coffman, EJ, Benes, CH, Gómez, HL, Baselga, J, Arteaga, CL, Rivera, MN, Dias-Santagata, D, Jain, RK & Engelman, JA 2011, 'BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors', Cancer Discovery, vol. 1, no. 4, pp. 352-365. https://doi.org/10.1158/2159-8290.CD-11-0106
Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E et al. BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors. Cancer Discovery. 2011 Sep 1;1(4):352-365. https://doi.org/10.1158/2159-8290.CD-11-0106
Faber, Anthony C. ; Corcoran, Ryan B. ; Ebi, Hiromichi ; Sequist, Lecia V. ; Waltman, Belinda A. ; Chung, Euiheon ; Incio, Joao ; Digumarthy, Subba R. ; Pollack, Sarah F. ; Song, Youngchul ; Muzikansky, Alona ; Lifshits, Eugene ; Roberge, Sylvie ; Coffman, Erik J. ; Benes, Cyril H. ; Gómez, Henry L. ; Baselga, José ; Arteaga, Carlos L. ; Rivera, Miguel N. ; Dias-Santagata, Dora ; Jain, Rakesh K. ; Engelman, Jeffrey A. / BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors. In: Cancer Discovery. 2011 ; Vol. 1, No. 4. pp. 352-365.
@article{8bf4bf196d984276a81678f38412d1c8,
title = "BIM expression in treatment-na{\"i}ve cancers predicts responsiveness to kinase inhibitors",
abstract = "Cancers with specific genetic mutations are susceptible to selective kinase inhibitors. However, there is a wide spectrum of benefit among cancers harboring the same sensitizing genetic mutations. Herein, we measured apoptotic rates among cell lines sharing the same driver oncogene following treatment with the corresponding kinase inhibitor. There was a wide range of kinase inhibitor-induced apoptosis despite comparable inhibition of the target and associated downstream signaling pathways. Surprisingly, pretreatment RNA levels of the BH3-only pro-apoptotic BIM strongly predicted the capacity of EGFR, HER2, and PI3K inhibitors to induce apoptosis in EGFR-mutant, HER2-amplified, and PIK3CA-mutant cancers, respectively, but BIM levels did not predict responsiveness to standard chemotherapies. Furthermore, BIM RNA levels in EGFR-mutant lung cancer specimens predicted response and duration of clinical benefit from EGFR inhibitors. These findings suggest assessment of BIM levels in treatment-na{\"i}ve tumor biopsies may indicate the degree of benefit from single-agent kinase inhibitors in multiple oncogene-addiction paradigms. Significance: In several oncogene-addiction paradigms, assessment of BIM RNA levels identifies those cancers that fail to have substantial apoptotic responses to kinase inhibitors. BIM RNA levels may be assessed in diagnostic cancer specimens to predict which patients will receive less benefit from single-agent kinase inhibitors.",
author = "Faber, {Anthony C.} and Corcoran, {Ryan B.} and Hiromichi Ebi and Sequist, {Lecia V.} and Waltman, {Belinda A.} and Euiheon Chung and Joao Incio and Digumarthy, {Subba R.} and Pollack, {Sarah F.} and Youngchul Song and Alona Muzikansky and Eugene Lifshits and Sylvie Roberge and Coffman, {Erik J.} and Benes, {Cyril H.} and G{\'o}mez, {Henry L.} and Jos{\'e} Baselga and Arteaga, {Carlos L.} and Rivera, {Miguel N.} and Dora Dias-Santagata and Jain, {Rakesh K.} and Engelman, {Jeffrey A.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1158/2159-8290.CD-11-0106",
language = "English (US)",
volume = "1",
pages = "352--365",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors

AU - Faber, Anthony C.

AU - Corcoran, Ryan B.

AU - Ebi, Hiromichi

AU - Sequist, Lecia V.

AU - Waltman, Belinda A.

AU - Chung, Euiheon

AU - Incio, Joao

AU - Digumarthy, Subba R.

AU - Pollack, Sarah F.

AU - Song, Youngchul

AU - Muzikansky, Alona

AU - Lifshits, Eugene

AU - Roberge, Sylvie

AU - Coffman, Erik J.

AU - Benes, Cyril H.

AU - Gómez, Henry L.

AU - Baselga, José

AU - Arteaga, Carlos L.

AU - Rivera, Miguel N.

AU - Dias-Santagata, Dora

AU - Jain, Rakesh K.

AU - Engelman, Jeffrey A.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Cancers with specific genetic mutations are susceptible to selective kinase inhibitors. However, there is a wide spectrum of benefit among cancers harboring the same sensitizing genetic mutations. Herein, we measured apoptotic rates among cell lines sharing the same driver oncogene following treatment with the corresponding kinase inhibitor. There was a wide range of kinase inhibitor-induced apoptosis despite comparable inhibition of the target and associated downstream signaling pathways. Surprisingly, pretreatment RNA levels of the BH3-only pro-apoptotic BIM strongly predicted the capacity of EGFR, HER2, and PI3K inhibitors to induce apoptosis in EGFR-mutant, HER2-amplified, and PIK3CA-mutant cancers, respectively, but BIM levels did not predict responsiveness to standard chemotherapies. Furthermore, BIM RNA levels in EGFR-mutant lung cancer specimens predicted response and duration of clinical benefit from EGFR inhibitors. These findings suggest assessment of BIM levels in treatment-naïve tumor biopsies may indicate the degree of benefit from single-agent kinase inhibitors in multiple oncogene-addiction paradigms. Significance: In several oncogene-addiction paradigms, assessment of BIM RNA levels identifies those cancers that fail to have substantial apoptotic responses to kinase inhibitors. BIM RNA levels may be assessed in diagnostic cancer specimens to predict which patients will receive less benefit from single-agent kinase inhibitors.

AB - Cancers with specific genetic mutations are susceptible to selective kinase inhibitors. However, there is a wide spectrum of benefit among cancers harboring the same sensitizing genetic mutations. Herein, we measured apoptotic rates among cell lines sharing the same driver oncogene following treatment with the corresponding kinase inhibitor. There was a wide range of kinase inhibitor-induced apoptosis despite comparable inhibition of the target and associated downstream signaling pathways. Surprisingly, pretreatment RNA levels of the BH3-only pro-apoptotic BIM strongly predicted the capacity of EGFR, HER2, and PI3K inhibitors to induce apoptosis in EGFR-mutant, HER2-amplified, and PIK3CA-mutant cancers, respectively, but BIM levels did not predict responsiveness to standard chemotherapies. Furthermore, BIM RNA levels in EGFR-mutant lung cancer specimens predicted response and duration of clinical benefit from EGFR inhibitors. These findings suggest assessment of BIM levels in treatment-naïve tumor biopsies may indicate the degree of benefit from single-agent kinase inhibitors in multiple oncogene-addiction paradigms. Significance: In several oncogene-addiction paradigms, assessment of BIM RNA levels identifies those cancers that fail to have substantial apoptotic responses to kinase inhibitors. BIM RNA levels may be assessed in diagnostic cancer specimens to predict which patients will receive less benefit from single-agent kinase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84857002194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857002194&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-11-0106

DO - 10.1158/2159-8290.CD-11-0106

M3 - Article

C2 - 22145099

AN - SCOPUS:84857002194

VL - 1

SP - 352

EP - 365

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 4

ER -